Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genscript Biotech ( (HK:1548) ) has shared an update.
Genscript Biotech Corporation announced that its associate, Legend Biotech, reported approximately $524 million in net trade sales for CARVYKTI® in the quarter ending September 2025. This figure highlights the product’s strong market performance under the collaboration with Janssen Biotech, Inc., indicating a positive impact on the company’s operations and industry positioning.
The most recent analyst rating on (HK:1548) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a biotechnology company incorporated in the Cayman Islands. The company is involved in the biotech industry, focusing on the development and commercialization of pharmaceutical products. It has a market focus on innovative therapies and collaborates with other biotech firms to enhance its product offerings.
Average Trading Volume: 20,762,692
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.41B
Learn more about 1548 stock on TipRanks’ Stock Analysis page.